NovoCare provides manufacturer support and a pharmacy access route for Wegovy. That can be useful when you already have a prescription or are trying to understand savings and self-pay options. It should not be confused with a clinical membership that automatically includes every part of assessment and follow-up.
This review uses current official Wegovy and NovoCare pages checked September 23, 2026. We did not submit a savings application, verify an individual insurance benefit, or fill a prescription. The prices described are published program terms with eligibility and other conditions.
One thing to keep with you
A manufacturer access program can help with the medication transaction; you still need an appropriate prescriber and continuing care.
Start by identifying the formulation
The current Wegovy label includes tablets and injections, and the manufacturer’s offer distinguishes them. Product form, strength, indication, age group, and administration instructions must be checked together. A prescription for one formulation should not be treated as permission to select another from a pricing menu.
Our pill-versus-injection guide explains the practical differences. An access page can help show available program routes, but the clinical choice belongs with your prescriber. It is also important not to transfer an indication from one formulation to another merely because both use the Wegovy name.
Checked with: Wegovy: current prescribing information · NovoCare: Wegovy pharmacy offer
Read the current tablet pricing by strength
The official self-pay terms list $149 per month for the 1.5 mg tablet strength, $199 for 4 mg, and $299 for 9 mg and 25 mg. One month is described as a bottle of 30 tablets. Eligibility, restrictions, and the manufacturer’s ability to change the program remain part of the offer.
These figures describe the price categories shown on the checked page, not a dosing recommendation or a guarantee that a reader should use the least expensive strength. Ask what the exact prescribed product will cost at the time of filling and whether any separate clinician charges apply.
Checked with: NovoCare: Wegovy pharmacy offer · Wegovy: current prescribing information
The injection promotion has a limit
For eligible new participants, the published injection offer describes $199 for each of two monthly fills of the introductory 0.25 mg and 0.5 mg strengths through December 31, 2026. The listed ongoing self-pay price is $349 for standard strengths, with $399 listed for Wegovy HD.
Do not interpret the introductory figure as an all-strength or permanent price. Our cost guide keeps those conditions attached to the numbers. Confirm the prescription, program eligibility, pharmacy channel, and current terms rather than relying on a screenshot or an offer from an earlier date.
Checked with: NovoCare: Wegovy pharmacy offer
Insurance is a separate conversation
Coverage depends on the specific plan, indication, prescription, and benefit rules. A manufacturer savings headline does not guarantee that an insurer will cover the medicine or that a person qualifies for every savings route. Self-pay and insurance-linked offers can have different restrictions and reimbursement consequences.
Use the official coverage tools and ask the insurer and pharmacy to confirm your actual situation. This review does not decide eligibility for government-benefit programs or provide reimbursement advice. Record the amount you expect to pay and how that figure could change after a deductible, renewal, or program update.
Checked with: NovoCare: checking Wegovy coverage · NovoCare: Wegovy pharmacy offer
Keep the care relationship in place
A dispensing or savings arrangement does not replace the clinician who evaluates your health history, reviews side effects, and decides whether treatment remains appropriate. Ask who will handle follow-up, refills, symptoms, and changes in other medicines. Keep the medication guide for the exact product available.
The safety article identifies questions to raise, including significant gastrointestinal symptoms, relevant medical history, and planned procedures. It is not a substitute for the full label. The pharmacy can clarify storage and device instructions, while the prescriber should resolve treatment decisions.
Checked with: Wegovy: current prescribing information · MedlinePlus: semaglutide information · NIDDK: prescription weight-management medicines
Compare the service you actually need
If you also need an online clinical care arrangement, Ro’s review explains a membership-plus-medication model. If you are considering a compounded offer, the CoreAge review and compounding guide discuss a different approval and regulatory category. These should not be flattened into one interchangeable price list.
We have not tested order fulfillment, customer-service response times, or individual coverage decisions. Our featured shortlist puts CoreAge first under a paid arrangement, not because an independent comparison established better clinical results than approved-product access through NovoCare.
Checked with: Ro: current program pricing · CoreAge Rx: semaglutide offer · FDA: concerns about unapproved GLP-1 products
Where we checked the facts
- Wegovy: current prescribing information
June 2026 label includes oral and injectable formulations with product-specific uses and instructions. Do not apply one formulation’s directions to another.
- NovoCare: Wegovy pharmacy offer
Manufacturer access and pricing terms checked September 23, 2026. Formulation, strength, eligibility and offer period affect cost.
- NovoCare: checking Wegovy coverage
Coverage and program information, not a guarantee for a particular insurance policy.
- MedlinePlus: semaglutide information
Patient medication information; the actual prescription and current product labeling govern use.
- NIDDK: prescription weight-management medicines
Background about clinical assessment and ongoing care; current product label controls newer formulation details.
- Ro: current program pricing
Membership and medication are separate charges. $39 introductory membership; $149 ongoing monthly or lower prepaid equivalents, subject to terms.
- CoreAge Rx: semaglutide offer
Commercial compounded-product offer, starting at $99/month when checked September 23, 2026. Not an FDA-approved generic or proof of comparative outcomes.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
